Anticholinergic Drugs Market Research Report - Global Forecast till 2024
Global Anticholinergic Drugs Market is expected to register a CAGR of 4.50% to reach USD 7,149.90 Million till 2024.
Global Anticholinergic Drugs Market: Information by Type (Synthetic Compounds, Natural, Semi-Synthetic Compounds), Application (Overactive Bladder, Parkinson’s Disease, Chronic Obstructive Pulmonary Disease, Muscle Spasms, Irritable Bowel Syndrome), Route of Administration (Oral, Parenteral, Topical), End User (Hospitals and Pharmacies) and Region - Forecast till 2024
The Global Anticholinergic Drugs Market is expected to register a CAGR of 4.50% to reach USD 7,149.90 Million till 2024. Anticholinergics drugs are a broad class of drugs that block acetylcholine-mediated neurotransmission in the smooth muscle, heart, central, and peripheral nervous systems. Acetylcholine is a neurotransmitter, or a chemical messenger released by nerve cells to send signals to other cells.
The increasing prevalence of chronic diseases and increasing investments and funding in the field of life science research has led to the growth of the global anticholinergic drugs market in recent years. Moreover, the aging population is expected to fuel market growth. However, side-effects of anticholinergic drugs and stringent regulations are projected to hamper the growth of the market during the assessment period.
The increasing prevalence of chronic diseases is expected to drive the market growth. According to the American Urological Association in 2018, about 33 million US population have an overactive bladder. About 30% of men and 40% of women in the United States shows OAB symptoms. National Institutes of Health (NIH) in 2017 estimated that about 50,000 US population are diagnosed with Parkinson’s disease each year.
Moreover, the rise in the older population will support the market growth of the anticholinergic drugs market. According to the World Health Organization (WHO), it is estimated that the world’s population aged 60 years and older would nearly double from 12% to 22% by 2050. In the US, more specifically, more than 20% of the total population would be aged 65 years or over by 2030.
The anticholinergic drugs market, based on product type, has been segmented into synthetic compounds, natural, and semi-synthetic compounds.
The anticholinergic drugs market, based on application, has been segmented into the overactive bladder, Parkinson’s disease, chronic obstructive pulmonary disease, muscle spasms, and irritable bowel syndrome.
On the basis of route of administration, the market is segmented into oral, parenteral, and topical.
On the basis of end user, the market is segmented into hospitals and pharmacies. The hospitals segment is expected to hold a major share with a market value of USD 4,218.6 million till 2024.
The prominent players in the Global Anticholinergic Drugs Market are Pfizer Inc. (US), Allergan Plc (US), Astellas Pharma Inc. (Japan), Johnson & Johnson Services Inc. (US), Teva Pharmaceutical Industries Ltd (Israel), Sanofi (France), GlaxoSmithKline Plc (UK), Boehringer Ingelheim International GmbH (Germany), Novartis AG (Switzerland), Mylan N.V. (US) and others.
Some of the key strategies followed by players operating in the global anticholinergic drugs market were innovation and product development.
The Global Anticholinergic Drugs Market, based on region, is divided into the Americas, Europe, Asia-Pacific, and the Middle East and Africa.
The Americas is expected to hold the largest share of the global anticholinergic drugs market. This owes to the rising geriatric population along with the high prevalence of CNS diseases and demand for effective therapies. The Europe market demonstrated substantial growth in the market due to the rising prevalence of bladder overactivity, increasing geriatric population, and rising healthcare expenditure. Germany held a share of 25.8% in the Western Europe anticholinergic drugs market in 2018. Asia-Pacific is estimated to be the fastest growing region in the global market due to the presence of a large number of research organizations and development of new infrastructure to support the healthcare industry. Also, the Middle East and Africa region is expected to show the least growth owing to low per capita income and lack of adequate healthcare spending.
In February 2016, Boehringer Ingelheim International GmbH, Spiriva Respimat had available for the treatment of asthma in adults and adolescents in the US.
In May 2015, Boehringer Ingelheim International GmbH received FDA approval for Stiolto Respimat Inhalation Spray. Market Segmentation
Global Anticholinergic Drugs Market, by Type
Global Anticholinergic Drugs Market, by Application
Chronic Obstructive Pulmonary Disease
Irritable Bowel Syndrome
Global Anticholinergic Drugs Market, by Route of administration
Global Anticholinergic Drugs Market, by End User
Global Anticholinergic Drugs Market, by Region
Rest of Western Europe
Rest of Asia-Pacific
Middle East & Africa
Available Additional Customizations
Anticholinergic Drugs Market, Industry Trends
Anticholinergic Drugs Market, Technology Trends and Assessment
Research and Development Organizations